The regulatory body first opened an investigation into Illumina's $7.1 billion acquisition of GRAIL in July 2021, expressing concern the deal would negatively impact competition and innovation in ...

Illumina Inc. was formally ordered to undo its $7 billion acquisition of cancer-test provider Grail Inc. as the European Union ramped up a legal fight over a deal the firms completed without its ...

U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc , pledging to keep selling its DNA sequencing services to other firms, as it ...

Biotech giant Illumina says it will undo its $7.1 billion purchase of the cancer-screening company Grail after losing legal battles with antitrust enforcers in the U.S. and Europe.

Illumina Inc.’s was ordered to unwind its $7 billion acquisition of cancer startup Grail by the Federal Trade Commission, an uncommon move by antitrust regulators who said the deal raises ...

Illumina said Thursday it has won in the Federal Trade Commission's case challenging its $7.1 billion acquisition of cancer detection company GRAIL.

Europe’s antitrust regulator on Tuesday moved to block San Diego’s Illumina from acquiring Grail — one week after a U.S. administrative law judge found that the blockbuster $7.1 billion ...

The U.S. Securities and Exchange Commission is investigating the $7.1 billion acquisition of Grail, a cancer screening startup, by San Diego’s DNA-sequencing giant Illumina.The San Diego-base… ...

U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of biotech firm Grail Inc, pledging to keep selling its DNA sequencing services to other firms, as it seeks ...